Arbutus Biopharma Corporation ABUS Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $23.71M-36.1% | $18.01M-50.4% | $22.41M-29.6% | $37.41M-40.4% | $37.08M-14.0% | ||
| $71.52M-5.4% | $73.46M-14.9% | $71.29M-25.7% | $60.68M-23.4% | $75.63M-12.2% | ||
| $178.74M+15,022% | $0-100% | $905K-43.7% | $1.03M-42.0% | $1.18M-44.7% | ||
| $277.01M+137% | $94.46M-25.8% | $97.44M-26.6% | $103.12M-30.4% | $116.81M-14.0% | ||
| $22K-86.9% | $32K-99.0% | $137K-96.1% | $148K-96.4% | $168K-96.2% | ||
| $277.16M+137% | $94.62M-28.2% | $97.71M-30.4% | $103.27M-35.5% | $117.01M-22.1% | ||
| $1.46M-34.7% | $1.17M-49.4% | $1.01M-56.3% | $1.32M-50.2% | $2.24M-40.2% | ||
| $5.11M-73.7% | $6.01M-61.5% | $5.18M-72.6% | $5.02M-77.8% | $19.43M-4.3% | ||
| —— | —— | —— | —— | —— | ||
| $16.99M-55.1% | $18.04M-47.5% | $20.31M-39.5% | $20.29M-46.0% | $37.85M+6.2% | ||
| $1.44B+2.0% | $1.42B+0.8% | $1.42B+0.8% | $1.42B+1.0% | $1.42B+2.8% | ||
| -$1.21B+11.7% | -$1.38B-2.5% | -$1.38B-3.2% | -$1.37B-4.1% | -$1.37B-5.9% | ||
| $260.18M+229% | $76.58M-21.4% | $77.4M-27.6% | $82.98M-32.2% | $79.16M-30.9% | ||
| $277.16M+137% | $94.62M-28.2% | $97.71M-30.4% | $103.27M-35.5% | $117.01M-22.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Arbutus Biopharma Corporation's total assets?
- Arbutus Biopharma Corporation (ABUS) holds $277.2M in total assets, up 136.9% year over year.
- How much debt does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation carries $631.0K in total debt against $260.2M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Arbutus Biopharma Corporation have?
- Arbutus Biopharma Corporation holds $23.7M in cash and equivalents.
- Can Arbutus Biopharma Corporation cover its short-term obligations?
- Its current ratio is 54.26 — current assets exceed current liabilities.
- Where does Arbutus Biopharma Corporation's balance sheet data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
